Bode BW, et al. - In a pediatric population with type 1 diabetes, researchers evaluated the effectiveness and safety of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp), both of them with basal insulin degludec. They conducted a multicenter trial that randomized 260 participants (1 to <18 years) to double-blind mealtime faster aspart, 258 to mealtime IAsp, and 259 to open-label postmeal faster aspart. The primary end point was change from baseline in glycated hemoglobin (HbA_1c) after 26 weeks of treatment. Mealtime and postmeal faster aspart with insulin degludec gave efficacious glycemic control without extra safety risks vs IAsp in adolescents and children with type 1 diabetes. As compared to IAsp, mealtime faster aspart offered better HbA_1c control.